Oncology Central

Highlights from the field of biomarkers in prostate cancer


Molecular changes in tissue adjacent to prostate cancer: a possible ‘carcinogenic filed effect’

Evaluation of: Crea F, Watahiki A, Quagliata L et al. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget 15(3), 764–774 (2014).

Most transcribed RNAs are not translated so protein encoding genes account for a small percentage of all RNAs. The noncoding transcripts include ribosomal, transfer and microRNAs. A number of miRNAs have been proposed as potential biomarkers of PCa [1].

lncRNA transcripts longer than 200 base pairs have not been extensively evaluated, but have been associated with dysregulated expression in malignant cells. Some have purported tissue specificity: PCGEM1 and the better known PCA3. The latter has been extensively evaluated as a diagnostic test for PCa and also potentially an indicator of disease volume. PCA3 has not been able to distinguish between aggressive and indolent disease.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.